Abstract Session 5

Co-Chair(s)

• 

  Meral Beksac, MD (she/her/hers)

  Professor of Hematology
  Istinye University
  Ankara, Turkey
• 

  Michael O'Dwyer, MD

  Professor of Hematology
  University of Galway, Galway, Ireland
  Galway, Ireland

Presentations:

• 9:00 AM – 9:12 AM East Coast USA Time

  OA – 01: Talquetamab (tal) + Daratumumab (dara) + Pomalidomide (pom) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 1b TRIMM‑2 Study
  

  Speaker: Nizar J. Bahlis, MD – Arnie Charbonneau Cancer Institute - University of Calgary
• 9:12 AM – 9:24 AM East Coast USA Time

  OA – 03: Talquetamab (tal) + Teclistamab (tec) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Phase 1B Results from RedirecTT-1 With >1 Year of Follow-Up
  

  Speaker: Yael C. Cohen, MD (she/her/hers) – Tel- Aviv Sourasky (Ichilov) Medical Center, and Faculty of health Science, Tel Aviv University, Tel Aviv, Israel
• 9:24 AM – 9:36 AM East Coast USA Time

  OA – 08: Safety and preliminary efficacy of BMS-986393, a GPRC5D CAR T cell therapy, in patients (pts) with relapsed/refractory (RR) multiple myeloma (MM) and 1–3 prior regimens: results from a phase 1 study
  

  Speaker: Myo Htut, MD – City of Hope Comprehensive Cancer Center
• 9:36 AM – 9:48 AM East Coast USA Time

  OA – 34: HBI0101, an anti-BCMA chimeric antigen receptor T-cell (CART) for relapsed/refractory multiple myeloma
  

  Speaker: Yael C. Cohen, MD (she/her/hers) – Tel- Aviv Sourasky (Ichilov) Medical Center, and Faculty of health Science, Tel Aviv University, Tel Aviv, Israel
• 9:48 AM – 10:00 AM East Coast USA Time

  OA – 60: The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma
  

  Speaker: Marc S. Raab, MD PhD (he/him/his) – Dept. of Medicine V Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany